Table 3.

Functional characterization of the PS mutants




C4BP

HPS54

PC/PS/PE vesicles
Wild-type rPS   4.4 ± 0.7   1.6 ± 0.3   9.0 ± 0.5  
GlaFII-ΔTSR-PS   11.4 ± 1.3   1.1 ± 0.2   17.0 ± 0.9  
GlaFII-PS   2.6 ± 0.2   1.4 ± 0.3   21.1 ± 1.5  
F1FII-GlaPS-PS   2.4 ± 0.3   1.4 ± 0.2   84.8 ± 3.4  
F2FII-GlaPS-PS   5.9 ± 0.4   5.0 ± 1.7   9.5 ± 1.1  
F12PS-GlaFII-PS
 
1.6 ± 0.2
 
3.6 ± 0.6
 
8.6 ± 0.8
 



C4BP

HPS54

PC/PS/PE vesicles
Wild-type rPS   4.4 ± 0.7   1.6 ± 0.3   9.0 ± 0.5  
GlaFII-ΔTSR-PS   11.4 ± 1.3   1.1 ± 0.2   17.0 ± 0.9  
GlaFII-PS   2.6 ± 0.2   1.4 ± 0.3   21.1 ± 1.5  
F1FII-GlaPS-PS   2.4 ± 0.3   1.4 ± 0.2   84.8 ± 3.4  
F2FII-GlaPS-PS   5.9 ± 0.4   5.0 ± 1.7   9.5 ± 1.1  
F12PS-GlaFII-PS
 
1.6 ± 0.2
 
3.6 ± 0.6
 
8.6 ± 0.8
 

All values are expressed as Kd app, nM.

Binding of wild-type rPS and PS mutants to immobilized C4BP, immobilized mAb HPS54, and immobilized phospholipid vesicles (PC/PS/PE vesicles) was evaluated as described in “Materials and methods.” Binding curves yielded the Kd app values, using nonlinear regression analysis of the A490 value as a function of the PS concentration.

or Create an Account

Close Modal
Close Modal